Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH-302 in Advanced Melanoma
NCT01864538Phase 2Terminated
- Sponsor
- ImmunoGenesis
- Start
- May 2013
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of evofosfamide in melanoma, sponsored by ImmunoGenesis. Primary endpoint: Overall Survival at 1 year. Started May 2013; status: terminated.
02
Drugs
evofosfamide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01864538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01864538.